Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis

Area of Science:

• Gastroenterology and Neurology
• Immunology and Epidemiology

Background:

• The co-occurrence of multiple sclerosis (MS) and inflammatory bowel disease (IBD) is suggested by shared epidemiological and immunological patterns.
• Previous observations indicate a higher incidence of IBD in MS patients and MS in IBD patients, hinting at a potential link.

Purpose of the Study:

• To quantitatively estimate the risk of concurrent IBD and MS comorbidity.
• To analyze this risk across different IBD subtypes (Crohn's disease and Ulcerative colitis) and data registry types (IBD and MS registries).

Main Methods:

• A meta-analysis of 10 case-control studies was conducted, encompassing 1,086,430 patients.
• Risk Ratios (RRs) were calculated for IBD/MS comorbidity.
• Subgroup analyses were performed based on registry type and IBD classification (CD vs. UC).

Main Results:

• The pooled Risk Ratio for IBD/MS comorbidity was 1.54 (95% CI 1.40-1.67), indicating a significant increased risk.
• No significant differences in comorbidity risk were observed between IBD and MS registries.
• Similarly, the risk of MS comorbidity was comparable between patients with Crohn's disease (RR 1.52) and Ulcerative colitis (RR 1.55).

Conclusions:

• Both IBD and MS patients face a substantially increased risk of developing the other condition.
• This heightened risk is consistent regardless of the specific type of IBD (CD or UC) or the registry source.
• The findings suggest a significant shared risk factor or pathway contributing to the comorbidity of IBD and MS.